M.M. Dillon & Co. (“Dillon”) acted as a placement agent for American Oriental Bioengineering (“AOB”) in its $115,000,000 convertible senior note PIPE. Dillon previously acted as lead manager for AOB on a $60,000,000 offering of common equity and warrants.
About American Oriental Bioengineering:
American Oriental Bioengineering is a leading, fully integrated, pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of pharmaceutical and healthcare products. The company’s product portfolio is comprised of prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products. AOB pharmaceutical products are well recognized in China and have been approved by the Chinese State Food and Drug Administration, or SFDA, based on demonstrated safety and efficacy.
The company sells its products primarily to hospitals, clinics, pharmacies and retail outlets at over 100,000 locations in all provinces, including rural areas and major cities in China, through the efforts of approximately 2,200 sales and marketing professionals. AOB has relationships with over 300 distributors to distribute our products to both urban and rural areas of China.
About M.M. Dillon & Co.
M.M. Dillon & Co. (formerly CRT Investment Banking LLC) is an employee owned partnership where industry and product specialists collaborate closely to provide creative, idea-driven advice and solutions to its institutional and corporate clients. M.M. Dillon offers public and private financing, M&A advisory and restructuring advisory services. M.M. Dillon’s team of experienced professionals provides execution capabilities for companies across a range of industry sectors. The firm’s senior banking professionals have a minimum of 20 years of experience with major Wall Street firms.